PPIF and myopathy: Muscle defects in collagen VI-deficient mice as well as in patients with collagen VI mutation-dependent myopathies are mitigated by pharmacological inhibition of the mitochondrial matrix protein peptidyl-prolyl cis-trans isomerase F (mouse Ppif: UniProtKB - Q99KR7; human PPIF: UniProtKB - P30405), a treatment considered to inhibit the Ca2+-dependent opening of the mitochondrial permeability transition pore (mPTP).30